Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based Sun Pharmaceutical Industries and Israel's Technion University have entered into an exclusive worldwide research and license agreement for the development of new class of oncology drugs.
Subscribe to our email newsletter
The deal aims at the development of a joint project, based on new findings by professor Aaron Ciechanover, Dr Gila Maor and professor Ofer Binah, that can potentially lead to the development of new anti-cancer drugs.
So far, the pre-clinical research was funded by Dr Alfred Mann.
Sun Pharma Business Development senior vice-president Kirti Ganorkar said: "This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its specialty pipeline.
"Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs."